Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects

Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects

Summary: Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide reductas...

Full description

Bibliographic Details
Main Authors: Gang Cheng, Micael Hardy, Paytsar Topchyan, Ryan Zander, Peter Volberding, Weiguo Cui, Balaraman Kalyanaraman
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:iScience
Subjects:
Drugs
Organic chemistry
Biological sciences
Immunology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221006416

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221006416

Similar Items